Emergent BioSolutions saw the highest growth of 0.99% in patent filings and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Emergent BioSolutions’s patent filings and grants. Buy the databook here.
Emergent BioSolutions has been focused on protecting inventions in United States(US) with two publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 33% filings and 100% grants. The United States(US), Australia(AU), and World Intellectual Property Organization(WIPO) patent Office are among the top ten patent offices where Emergent BioSolutions is filings its patents. Among the top granted patent authorities, Emergent BioSolutions has 100% of its grants in United States(US).
Gilead Sciences and Roche could be the strongest competitors for Emergent BioSolutions
Patents related to nanomedicine and rare diseases lead Emergent BioSolutions's portfolio
Emergent BioSolutions has the highest number of patents in nanomedicine followed by, rare diseases. For nanomedicine, nearly 50% of patents were filed and no patents were granted in Q2 2024.
Encephalitis related patents lead Emergent BioSolutions portfolio followed by hepatitis b, and type 1 diabetes (juvenile diabetes)
Emergent BioSolutions has highest number of patents in encephalitis followed by hepatitis b, type 1 diabetes (juvenile diabetes), diabetes, and western equine encephalitis.
For comprehensive analysis of Emergent BioSolutions's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.